Q-omics provides the consensus-scored SBDS profile across patient tissues and cancer cell-line models. SBDS expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SBDS is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SBDS protein abundance shows 23,794 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, BLCA, and PDAC as cancer lineages where SBDS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SBDS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SBDS survival associations across molecular data types. SBDS RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SBDS RNA expression–survival associations across cancer types. High SBDS expression shows unfavorable associations in HNSC, SCLC, CESC, UCEC and BLCA, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SBDS RNA expression.
This table summarizes SBDS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SBDS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SBDS shows lower tumor expression in BLCA, LUSC, KICH, LUAD and UCEC and higher tumor expression in LIHC. The BLCA box plot shows higher SBDS RNA expression in normal versus tumor tissue (log2 FC = −1.080, t-test p < 0.001).
This table shows molecular features associated with SBDS in patient tissues and cancer cell lines. In patient samples, SBDS shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SBDS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
